- Home
- BTMD vs MGNX Comparison
BTMD vs MGNX Comparison
Compare BTMD & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- MGNX
- Stock Information
- Founded
- BTMD 2012
- MGNX 2000
- Country
- BTMD United States
- MGNX United States
- Employees
- BTMD N/A
- MGNX N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- MGNX Health Care
- Exchange
- BTMD Nasdaq
- MGNX Nasdaq
- Market Cap
- BTMD 90.0M
- MGNX 99.7M
- IPO Year
- BTMD N/A
- MGNX 2013
- Fundamental
- Price
- BTMD $2.74
- MGNX $1.85
- Analyst Decision
- BTMD Buy
- MGNX Hold
- Analyst Count
- BTMD 2
- MGNX 6
- Target Price
- BTMD $6.00
- MGNX $3.20
- AVG Volume (30 Days)
- BTMD 104.4K
- MGNX 726.3K
- Earning Date
- BTMD 11-05-2025
- MGNX 11-04-2025
- Dividend Yield
- BTMD N/A
- MGNX N/A
- EPS Growth
- BTMD 642.53
- MGNX N/A
- EPS
- BTMD 0.88
- MGNX N/A
- Revenue
- BTMD $199,073,000.00
- MGNX $165,495,000.00
- Revenue This Year
- BTMD N/A
- MGNX N/A
- Revenue Next Year
- BTMD $4.85
- MGNX N/A
- P/E Ratio
- BTMD $3.11
- MGNX N/A
- Revenue Growth
- BTMD 6.32
- MGNX 303.47
- 52 Week Low
- BTMD $2.71
- MGNX $0.99
- 52 Week High
- BTMD $6.98
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- BTMD 37.74
- MGNX 55.15
- Support Level
- BTMD $2.80
- MGNX $1.82
- Resistance Level
- BTMD $3.01
- MGNX $2.15
- Average True Range (ATR)
- BTMD 0.14
- MGNX 0.13
- MACD
- BTMD 0.01
- MGNX 0.02
- Stochastic Oscillator
- BTMD 5.42
- MGNX 49.15
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.